Cargando…

Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age

PURPOSE: To compare refractive and biometric outcomes in patients with type 1 retinopathy of prematurity (ROP) treated with intravitreal injection of ranibizumab (IVR) versus bevacizumab (IVB), at a corrected age of 3 years. METHODS: A retrospective case series compared cycloplegic refractive status...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yen-Chih, Chen, San-Ni, Yang, Benjamin Chi-Lan, Lee, Kun-Hsien, Chuang, Chih-Chun, Cheng, Chieh-Yin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866885/
https://www.ncbi.nlm.nih.gov/pubmed/29713524
http://dx.doi.org/10.1155/2018/4565216
_version_ 1783308891080097792
author Chen, Yen-Chih
Chen, San-Ni
Yang, Benjamin Chi-Lan
Lee, Kun-Hsien
Chuang, Chih-Chun
Cheng, Chieh-Yin
author_facet Chen, Yen-Chih
Chen, San-Ni
Yang, Benjamin Chi-Lan
Lee, Kun-Hsien
Chuang, Chih-Chun
Cheng, Chieh-Yin
author_sort Chen, Yen-Chih
collection PubMed
description PURPOSE: To compare refractive and biometric outcomes in patients with type 1 retinopathy of prematurity (ROP) treated with intravitreal injection of ranibizumab (IVR) versus bevacizumab (IVB), at a corrected age of 3 years. METHODS: A retrospective case series compared cycloplegic refractive statuses and biometric statuses in patients who received either IVR or IVB for type 1 ROP, from April 2011 to April 2014. RESULTS: A total of 62 eyes (33 patients) with type 1 ROP were evaluated (26 eyes in 13 IVR patients and 36 eyes in 20 IVB patients). There were no differences in birth statuses including gestational age and birth body weight between the two groups. The prevalence of refractive error greater than 1 D was higher in the IVB group (p = 0.03), and there was a higher prevalence of high myopia (<−5.0 D, p = 0.03) in the IVB group. Comparisons in biometric finding showed that IVB patients had shallower anterior chamber depth (p = 0.01). CONCLUSION: Both IVR and IVB showed low refractive errors, even followed at the corrected age of 3 years. No difference was noted between the two groups in refractive statuses. However, IVB was associated with shallower anterior chamber and higher prevalence of refractive error at the corrected age of 3 years. This trial is registered with NCT03334513.
format Online
Article
Text
id pubmed-5866885
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-58668852018-04-30 Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age Chen, Yen-Chih Chen, San-Ni Yang, Benjamin Chi-Lan Lee, Kun-Hsien Chuang, Chih-Chun Cheng, Chieh-Yin J Ophthalmol Clinical Study PURPOSE: To compare refractive and biometric outcomes in patients with type 1 retinopathy of prematurity (ROP) treated with intravitreal injection of ranibizumab (IVR) versus bevacizumab (IVB), at a corrected age of 3 years. METHODS: A retrospective case series compared cycloplegic refractive statuses and biometric statuses in patients who received either IVR or IVB for type 1 ROP, from April 2011 to April 2014. RESULTS: A total of 62 eyes (33 patients) with type 1 ROP were evaluated (26 eyes in 13 IVR patients and 36 eyes in 20 IVB patients). There were no differences in birth statuses including gestational age and birth body weight between the two groups. The prevalence of refractive error greater than 1 D was higher in the IVB group (p = 0.03), and there was a higher prevalence of high myopia (<−5.0 D, p = 0.03) in the IVB group. Comparisons in biometric finding showed that IVB patients had shallower anterior chamber depth (p = 0.01). CONCLUSION: Both IVR and IVB showed low refractive errors, even followed at the corrected age of 3 years. No difference was noted between the two groups in refractive statuses. However, IVB was associated with shallower anterior chamber and higher prevalence of refractive error at the corrected age of 3 years. This trial is registered with NCT03334513. Hindawi 2018-03-11 /pmc/articles/PMC5866885/ /pubmed/29713524 http://dx.doi.org/10.1155/2018/4565216 Text en Copyright © 2018 Yen-Chih Chen et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Chen, Yen-Chih
Chen, San-Ni
Yang, Benjamin Chi-Lan
Lee, Kun-Hsien
Chuang, Chih-Chun
Cheng, Chieh-Yin
Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age
title Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age
title_full Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age
title_fullStr Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age
title_full_unstemmed Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age
title_short Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age
title_sort refractive and biometric outcomes in patients with retinopathy of prematurity treated with intravitreal injection of ranibizumab as compared with bevacizumab: a clinical study of correction at three years of age
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866885/
https://www.ncbi.nlm.nih.gov/pubmed/29713524
http://dx.doi.org/10.1155/2018/4565216
work_keys_str_mv AT chenyenchih refractiveandbiometricoutcomesinpatientswithretinopathyofprematuritytreatedwithintravitrealinjectionofranibizumabascomparedwithbevacizumabaclinicalstudyofcorrectionatthreeyearsofage
AT chensanni refractiveandbiometricoutcomesinpatientswithretinopathyofprematuritytreatedwithintravitrealinjectionofranibizumabascomparedwithbevacizumabaclinicalstudyofcorrectionatthreeyearsofage
AT yangbenjaminchilan refractiveandbiometricoutcomesinpatientswithretinopathyofprematuritytreatedwithintravitrealinjectionofranibizumabascomparedwithbevacizumabaclinicalstudyofcorrectionatthreeyearsofage
AT leekunhsien refractiveandbiometricoutcomesinpatientswithretinopathyofprematuritytreatedwithintravitrealinjectionofranibizumabascomparedwithbevacizumabaclinicalstudyofcorrectionatthreeyearsofage
AT chuangchihchun refractiveandbiometricoutcomesinpatientswithretinopathyofprematuritytreatedwithintravitrealinjectionofranibizumabascomparedwithbevacizumabaclinicalstudyofcorrectionatthreeyearsofage
AT chengchiehyin refractiveandbiometricoutcomesinpatientswithretinopathyofprematuritytreatedwithintravitrealinjectionofranibizumabascomparedwithbevacizumabaclinicalstudyofcorrectionatthreeyearsofage